advances in testing: a personalized, ctdna assay for mrd detection and surveillance
Published 3 years ago • 3.6K plays • Length 18:43Download video MP4
Download video MP3
Similar videos
-
2:19
introducing signatera, a personalized, tumor-informed test
-
49:45
a ctdna assay for remote monitoring and risk stratification
-
1:39
about signatera and ctdna
-
2:22
signatera for immunotherapy response monitoring
-
1:05:21
ctdna and mrd testing | colorectal cancer care tools for surveillance
-
2:37
axel grothey, md | importance of ctdna and mrd testing
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
58:43
2021 gi asco recap
-
3:25
understand ctdna testing
-
3:26
steven's story: long-term stable disease on immunotherapy
-
4:36
signacase: a case review: unexplained elevated cea
-
1:23
role of ctdna in mrd
-
35:05
a ctdna assay for remote monitoring and risk stratification of crc patients
-
4:17
precise molecular residual disease (mrd) test
-
1:07
ctdna mrd detection in patients with nsclc
-
8:08
asco 2021 lung recap: mylung consortium: overall biomarker testing
-
51:12
ccf webinar: asco recap and highlights
-
6:10
asco 2021 lung recap: circulatory tumor dna
-
2:53
the emerging role of mrd in colorectal cancer decision making
-
8:13
asco 2021 lung recap: fda analysis of immunotherapy with or without chemo in adv nsclc and low pdl-1
-
2:27
the current state of mrd testing in colorectal cancer
-
2:48
is the cancer coming back? using signatera to detect molecular residual disease (mrd)